Last reviewed · How we verify
NCT04191213: GA&SCA
Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients
Phase 2, PHASE3 trial testing Acacia Senegal extract in Sickle Cell Anemia in Children in 100 participants. Status unknown.
15 June 2020
Quick facts
| Lead sponsor | Al-Neelain University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 100 |
| Start date | 15 February 2020 |
| Primary completion | 15 June 2020 |
| Estimated completion | 15 July 2020 |
| Sites | 1 location across Sudan |
Drugs / interventions tested
- Acacia Senegal extract
- Pectin (PECTIN) — full drug profile →
Conditions studied
- Sickle Cell Anemia in Children — all drugs for Sickle Cell Anemia in Children →
Sponsor
Al-Neelain University
Who can join
Adults 3 to 18, any sex, with Sickle Cell Anemia in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy.
Vona R, Sposi NM, Mattia L, Gambardella L, et al · · 2021 · cited 65× · PMID 33669171 · DOI 10.3390/antiox10020296 -
Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.
Ogu UO, Badamosi NU, Camacho PE, Freire AX, et al · · 2021 · cited 23× · PMID 33658881 · DOI 10.2147/jbm.s291394 -
Investigating the Potential Use of Andrographolide as a Coadjuvant in Sickle Cell Anemia Therapy.
Gour A, Kotwal P, Dogra A, Kour D, et al · · 2022 · cited 2× · PMID 35474831 · DOI 10.1021/acsomega.1c07339
Verify or expand the search:
- PubMed search for NCT04191213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acacia Senegal extract
Trials testing the same drug.
- NCT04215380 — Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome · NA · unknown
Other recruiting trials for Sickle Cell Anemia in Children
Currently open trials in the same condition.
- NCT05285917 — Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa · Phase 3 · recruiting
- NCT06387758 — Low Systemic/High Local Exercise Load in Peds SCD · NA · recruiting
Other Al-Neelain University trials
Trials by the same sponsor.
- NCT04381871 — Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04191213 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Neelain University
- Last refreshed: 28 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing